Heart drug swap trial aims for safer, easier treatment

NCT ID NCT07600177

Recruiting now Disease control Sponsor: Oregon Health and Science University Source: ClinicalTrials.gov ↗

First seen May 23, 2026 · Last updated May 23, 2026

Summary

This study looks at whether patients with a thickened heart muscle condition can safely switch from one medication (mavacamten) to a newer one (aficamten). About 40 adults currently taking mavacamten will be monitored for side effects and heart function changes. The goal is to see if the switch is safe and effective in controlling the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTROPHIC CARDIOMYOPATHY (HCM) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Oregon Health & Science University
RECRUITING

Portland, Oregon, 97239, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
St. Luke's Hospital - Mid America Heart Institute
NOT_YET_RECRUITING

Kansas City, Missouri, 64111, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

HYPERTROPHIC CARDIOMYOPATHY (HCM)